0001596770-14-000065.txt : 20141110 0001596770-14-000065.hdr.sgml : 20141110 20141110162149 ACCESSION NUMBER: 0001596770-14-000065 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20141110 DATE AS OF CHANGE: 20141110 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81821 FILM NUMBER: 141208946 BUSINESS ADDRESS: STREET 1: 75 KNEELAND STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02111 BUSINESS PHONE: (617) 275-0040 MAIL ADDRESS: STREET 1: 75 KNEELAND STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02111 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Roumell Asset Management, LLC CENTRAL INDEX KEY: 0001331693 IRS NUMBER: 522145132 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 2 WISCONSIN CIR STREET 2: SUITE 660 CITY: CHEVY CHASE STATE: MD ZIP: 20815 BUSINESS PHONE: 301-656-8500 MAIL ADDRESS: STREET 1: 2 WISCONSIN CIR STREET 2: SUITE 660 CITY: CHEVY CHASE STATE: MD ZIP: 20815 SC 13G/A 1 schedule13ga.htm PARATEK SCHEDULE 13GA 11-10-14 schedule13ga.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 
 
SCHEDULE 13G/A
(Amendment No. 2)



Under the Securities Exchange Act of 1934


Paratek Pharmaceuticals, Inc.
(formerly, Transcept Pharmaceuticals, Inc.)
(Name of Issuer)


Common Stock
(Title of Class of Securities)


699374302
(CUSIP Number)


October 30, 2014
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x           Rule 13d-1(b)

o           Rule 13d-1(c)

o           Rule 13d-1(d)


The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

 
 
 
CUSIP No. 699374302
13G/A
Page 2 of 6 Pages



 
1.
Name of Reporting Person.
I.R.S. Identification Nos. of above persons (entities only).
 
Roumell Asset Management, LLC (“RAM”)
52-2145132
 
 
2.
Check the Appropriate Box if a Member of a Group
 
 
(a) o
(b) o
 
 
3.
SEC Use Only
 
 
 
4.
Citizenship or Place of Organization
 
Maryland
 
 
Number of
 
Shares
 
Beneficially
 
Owned by
 
Each
 
Reporting
 
Person
 
With:
 
 
5.
Sole Voting Power
 
128,305*
 
6.
Shared Voting Power
 
134,989
 
7.
Sole Dispositive Power
 
128,305*
 
8.
Shared Dispositive Power
 
134,989
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
263,294
 
 
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
o Not Applicable
 
 
11.
Percent of Class Represented by Amount in Row (9)
 
Approximately 1.8% (based on the 14,417,936 shares of common stock outstanding as of October 30, 2014, as reported in Item 2.01 of the Issuer’s Current Report on Form 8-K dated October 30, 2014 and filed on October 31, 2014 (the “Form 8-K”)).
 
 
12.
Type of Reporting Person
 
IA
 

* Represents shares held by the Roumell Opportunistic Value Fund (the “Fund”) and includes 86,760 shares expected to be received as part of the Paratek Financing (as defined in the Form 8-K).

 
 
 
CUSIP No. 699374302
13G/A
Page 3 of 6 Pages



 
1.
Name of Reporting Person.
I.R.S. Identification Nos. of above persons (entities only).
 
James C. Roumell (“Roumell”)
 
 
2.
Check the Appropriate Box if a Member of a Group
 
(c) o
(d) o
 
3.
SEC Use Only
 
 
4.
Citizenship or Place of Organization
 
U.S.A.
 
 
Number of
 
Shares
 
Beneficially
 
Owned by
 
Each
 
Reporting
 
Person
 
With:
 
 
5.
Sole Voting Power
 
130,345*
 
6.
Shared Voting Power
 
134,989**
 
7.
Sole Dispositive Power
 
130,345*
 
8.
Shared Dispositive Power
 
134,989**
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
265,334 **
 
 
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
o Not Applicable
 
 
11.
Percent of Class Represented by Amount in Row (9)
 
Approximately 1.8% (based on the 14,417,936 shares of common stock outstanding as of October 30, 2014, as reported in the Form 8-K).
 
 
12.
Type of Reporting Person
 
IN
 

*      Includes 128,305 shares held by the Fund.

 
**
Roumell is the President of RAM and holds a controlling percentage of its outstanding voting securities and, as a result of his position with and ownership of securities of RAM, Roumell could be deemed the beneficial owner of the shares held by RAM.
 
 
 
 
 
 
CUSIP No. 699374302
13G/A
Page 4 of 6 Pages
 
Item 1(a).
Name of Issuer:
 
 
Paratek Pharmaceuticals, Inc.
 
Item 1(b).
Address of Issuer’s Principal Executive Offices:
 
 
75 Kneeland Street, 6th Floor
Boston, Massachusetts  02111
 
Item 2(a).
Name of Persons Filing:
 
 
1.  Roumell Asset Management, LLC
 
2.  James C. Roumell
 
Item 2(b).
Address of Principal Business Office or, if none, Residence:
 
 
2 Wisconsin Circle, Suite 660, Chevy Chase, MD  20815
 
Item 2(c).
Citizenship:
 
 
1.  RAM – Maryland
 
2.  Roumell – U.S.A.
 
Item 2(d).
Title of Class of Securities:
 
 
Common Stock
 
Item 2(e).
CUSIP Number:
 
 
699374302
 
 
Item 3.
If this statement is filed pursuant to Rule 13(d)-1(b), or 13(d)-2(b), or (c), check whether the person filing is a:
 
  (a) o Broker or dealer registered under Section 15 of the Exchange.
       
  (b) o
Bank as defined in Section 3(a)(6) of the Exchange Act.
       
  (c) o
Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
  (d) o Investment company registered under Section 8 of the Investment Company Act of 1940.
       
  (e) x * An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
       
  (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
       
  (g) x
* A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
       
  (h) o A savings association as defined in SEction 3(b) of the Federal Deposit Insurance Act.
       
  (i) o
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
       
  (j) o
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
 
 
*
RAM is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940.  Roumell is the President of RAM and holds a controlling percentage of its outstanding voting securities.  Roumell is joining in this filing on Schedule 13G/A pursuant to Rule 13d-1(k)(1).
 
 
 
 
 
CUSIP No. 699374302
13G/A
Page 5 of 6 Pages
 
Item 4.                                Ownership.
 
(a) 
 
Amount beneficially owned:
 
See Items 5-11 on the cover sheets of this Schedule 13G/A.
 
(b) 
 
Percent of class:
 
Approximately 1.8% (based on the 14,417,936 shares of common stock outstanding as of October 30, 2014, as reported in Item 2.01 of the Issuer’s Current Report on Form 8-K dated October 30, 2014 and filed on October 31, 2014).
 
 
(c) 
 
Number of shares as to which each person has:
 
(i)
Sole power to vote or to direct the vote
 
130,345 (includes 2,040 shares
held by Roumell)
 
(ii)
 
Shared power to vote or to direct the vote
134,989
 (through RAM)
 
(iii) 
 
Sole power to dispose or to direct the disposition of
 
130,345 (includes 2,040 shares
held by Roumell)
 
(iv) 
 
Shared power to dispose or to direct the disposition of
 
134,989
(through RAM)
 
Item 5.                    Ownership of Five Percent or Less of a Class.
 
If this statement is being filed to report the facts that as of the date hereof the reporting persons have ceased to be the beneficial owners of more than 5% of the class of securities, check the following x.
 
Item 6.                    Ownership of More than Five Percent on Behalf of Another Person.
 
Not applicable.
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
Not applicable.
 
Item 8.
Identification and Classification of Members of the Group.
 
Not applicable.
 
Item 9.
Notice of Dissolution Group.
 
Not applicable.
 
Item. 10.
Certification.
 
By signing below, the undersigned (i) certify that, to the best of their knowledge and belief, the securities reported herein were acquired in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect and (ii) hereby declare and affirm that the filing of this Schedule 13G/A shall not be construed as an admission that either of the reporting persons is the beneficial owner of the securities reported herein, which beneficial ownership is hereby expressly disclaimed, except to the extent of their respective pecuniary interest therein.
 

 
 
 
 
CUSIP No. 699374302
13G/A
Page 6 of 6 Pages

SIGNATURES
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
November 10, 2014
(Date)
 
 
  /s/ James C. Roumell
(Signature)
 
Roumell Asset Management, LLC
By: James C. Roumell, President
(Name/Title)

November 10, 2014
(Date)
 
 
/s/ James C. Roumell
(Signature)
 
 
James C. Roumell
(Name)

 
 
 

JOINT FILING AGREEMENT



In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them this Schedule 13G (including further amendments thereto) with respect to the common stock of Transcept Pharmaceuticals, Inc., and that this Joint Filing Agreement be included as an exhibit to such joint filing.

This Joint Filing Agreement may be executed in one or more counterparts, and each such counterpart shall be an original but all of which, taken together, shall constitute but one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint filing Agreement as of this 18th day of December 2013.


 

    By:           /s/ James C. Roumell                                                      
    James C. Roumell




    ROUMELL ASSET MANAGEMENT, LLC



    By:           /s/ James C. Roumell                                                      
    James C. Roumell, President